NDAINTRAVENOUSPOWDER
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DAPTOMYCIN (daptomycin) by MAIA Biotechnology is [see clinical pharmacology ()]. First approved in 2024.
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin is a lipopeptide antibiotic administered intravenously as a powder formulation, approved by the FDA on November 21, 2024. It works through a mechanism that disrupts bacterial cell membrane function, making it effective against gram-positive infections. The drug is indicated for serious infections caused by susceptible gram-positive bacteria.
Growth
Recent approval positions this as an emerging growth product with opportunity to build market share in the IV antibiotic space; team expansion likely as commercial infrastructure develops.
Mechanism of Action
[see Clinical Pharmacology ()].
Pharmacologic Class:
Lipopeptide Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
Started Dec 2018
18 enrolled
BacteremiaSoft Tissue InfectionsSkin Diseases, Infectious
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
Started May 2014
12 enrolled
Drug InteractionsPharmacokinetics
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
Started Sep 2013
149 enrolled
Acute Hematogenous Osteomyelitis
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
Started Nov 2012
82 enrolled
Bacteremia
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Started May 2012
10 enrolled
Nosocomial InfectionHealthcare-associated Infection
Worked on DAPTOMYCIN at MAIA Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.